Augurex Announces UK Conformity Assessed (UKCA) Authorization for JOINTstat®, Expanding Access to Cutting-Edge Rheumatoid Arthritis Testing in Great Britain

Contributed by: Business Wire

Logo

Tags

Health

Neurology

Other Health

General Health

Clinical Trials

Pharmaceutical

Biotechnology

Augurex Life Sciences

More Like This

AliveDx Expands Autoimmune Menu with IVDR-CE Marked MosaiQ AiPlex® CTDplus Multiplex Assay to Aid in Diagnosing Systemic Autoimmune Rheumatic Diseases and Streamline Laboratory Workflow

XBiotech Pauses Rheumatology program

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis

Celltrion showcases promising results in phase III study for CT-P47, a biosimilar candidate of RoActemra® (tocilizumab) in patients with rheumatoid arthritis (RA) at EULAR 2024

PR Newswire associated0

Contura Orthopedics Expands to Canada, Bringing Arthrosamid® to North America

AliveDx receives three IVDR CE marks for its Multiplexed Autoimmune Diagnostics Solution

Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics

Roche launches three new Factor Xa inhibitor coagulation tests to meet growing patient need